SCHEMBL31411455

SCHEMBL31411455

Cc1ccc(S(=O)(=O)n2ncc3cc(F)cc(F)c32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
KMT2A Q03164 5/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
RORC P51449 2/20 0.39
SLC9A1 P19634 1/20 0.39
LMNA P02545 2/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
ACLY P53396 1/20 0.37
OPRD1 P41143 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31411280 0.86 KMT2A (0.45) MAPTKMT2AMEN1ALDH1A1NR1H2
SCHEMBL29937579 0.77 OPRD1 (0.47) MAPTKMT2AMEN1OPRD1
SCHEMBL29804026 0.77 OPRD1 (0.48) MAPTKMT2AMEN1ALDH1A1NR1H2
SCHEMBL26551198 0.75 KMT2A (0.46) MAPTKMT2AMEN1ALDH1A1NR1H2
SCHEMBL17504506 0.74 L3MBTL1 (0.48) MAPTALDH1A1TSHRPOLBLMNA
SCHEMBL31411482 0.73 TSHR (0.43) MAPTKMT2AMEN1ALDH1A1TSHR
SCHEMBL31411447 0.71 MAPT (0.40) MAPTKMT2AMEN1ALDH1A1TSHR
SCHEMBL6977740 0.71 HDAC3 (0.57) MAPTKMT2AMEN1ALDH1A1NR1H2
SCHEMBL29976068 0.71 HDAC3 (0.57) MAPTKMT2AMEN1ALDH1A1NR1H2
SCHEMBL19213030 0.69 HTR6 (0.41) MAPTSMN1; SMN2POLBLMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735425-A1 COMPOUNDS Psylo Pty Ltd (AU) 2026-05-06 EP disclosed
US-20250353818-A1 Compounds Psylo Pty Ltd (AU) 2025-11-20 US disclosed
US-12428380-B2 Compounds Psylo Pty Ltd (AU) 2025-09-30 US disclosed
US-20250214943-A1 Compounds Psylo Pty Ltd (AU) 2025-07-03 US disclosed
WO-2025000053-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-01-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214943-A1 Compounds NLN, SLC18A2, PYGB MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885
US-12428380-B2 Compounds NLN, SLC18A2, PYGB MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885
US-20250353818-A1 Compounds NLN, SLC18A2, PYGB MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.